MTS Health Partners’ Post

Following in the footsteps of Johnson & Johnson (JNJ) and Eli Lilly (LLY), Sanofi (NASDAQ:SNY) has become the latest pharma challenging #HHS' #340B program that provides discounted drugs to hospitals and clinics that primarily serve poor and underinsured patients.   Although Sanofi has not filed suit against HHS as the other two drugmakers have, the French company intends to send a letter to hospitals outlining how it plans to offer discounts through the program going forward, according to The Wall Street Journal.   Based on that letter, the newspaper said that hospitals will now have to provide medical and pharmacy claims data before it will offer discounts on its drugs to hospitals.   Under this scheme, hospitals would pay full price for Sanofi's meds and would receive reimbursement for the discounted rate only after the claims data is received. Currently, the 340B program provides that the hospitals receive the drugs at the discounted rate when they first purchase them. Johnson & Johnson U.S. Department of Health and Human Services (HHS) Eli Lilly and Company Sanofi US Government Accountability Office Office (GAO) https://lnkd.in/gwP4UkA8   Challenges - https://lnkd.in/guEckMH2 An explosion in third-party involvement fueled a dramatic expansion in the 340B program. The GAO reported that the number of pharmacies contracted by covered entities increased from 1,300 in 2010 to 23,000 in 2020. As HRSA’s own audits have found, covered entities’ increased use of unlimited contract pharmacy arrangements has produced a sharp rise in unlawful drug diversion and duplicate discounting. Blog – Healthcare Pharma, and Biotech – Analysis and Commentary – September 2024 - https://lnkd.in/e5Sz3Z-C  

In case you missed it, our Founder and CEO Joe Cardosi participated in an insightful panel discussion at Empower 2024 alongside John Scott of Agios Pharmaceuticals and Ernie Shopes of Inovalon.      The focus? Collaboration between pharmacy and pharma to advance patient access. Joe shares how FMH orchestrates stakeholders across the specialty pharmacy ecosystem-unbiasedly and efficiently-to ensure patients receive high-quality care when they need it most.      The main takeaway? Keep the patient at the center of every decision while embracing innovation to reduce inefficiencies and improve outcomes.     Watch the full panel discussion here: https://lnkd.in/gmp_iMsf 

Let’s connect and create impactful solutions for a healthier future! EVA pharma RauCon Business Development See you in Dublin! 🌟 . . . . . . #EuroPLX #PharmaIndustry #BusinessDevelopment #Partnerships #Collaboration #Innovation #Healthcare #Biotech #Pharmaceuticals #LifeSciences #DrugDevelopment #HealthcareInnovation #ClinicalResearch #PharmaBusiness #HealthTech #GlobalHealth #MedicalResearch #PharmaPartnerships #BusinessGrowth #IndustryLeaders #HealthSolution

CVC Capital Partners, a Luxembourg-based private equity and investment advisory firm, agreed to acquire the Therakos business of Mallinckrodt Pharmaceuticals, a global specialty pharmaceutical company, for $925m. "Today's announcement underscores our commitment to executing on our strategic priorities and creating value for our stakeholders. This transaction provides the Therakos business with an ideal partner to invest in its continued growth, and we look forward to closely working with CVC to transition Therakos for the benefit of patients, healthcare providers, partners and employees. I thank the Therakos team for their ongoing commitment and dedication to improving the lives of patients," Sigurdur Olafsson, Mallinckrodt President and CEO. Mallinckrodt is advised by Lazard, A&O Shearman, Arthur Cox LLP, Wachtell, Lipton, Rosen & Katz (led by Victor Goldfeld) and Joele Frank (led by Michael Freitag, Aaron Palash and Aura Reinhard). CVC Capital is advised by Candesic, PwC, UBS and Freshfields Bruckhaus Deringer. #MergersAcquisitionsDivestitures #PrivateEquity #Pharmaceutical

Poolbeg Pharma plc #POLB & HOOKIPA Pharma Inc. - Potential Combination update ✅ Gilead Sciences intends to vote with HOOKIPA Board recommendation & to participate in proposed fundraise up to $8.7495m consistent with it's contractual obligations read: https://lnkd.in/eEqKzu3j

Firebrick Pharma achieves 111% sales growth for Nasodine in the last quarter, announcing strategic partnerships in Singapore. Read More https://lnkd.in/gT6aTwp6 #FirebrickPharma, #Nasodine, #SalesGrowth, #FinancialPerformance

We are excited to announce that Immedica has entered into an agreement to acquire Marinus Pharmaceuticals, Inc., a significant step in strengthening our position as a leading global rare disease company. This transformative acquisition, valued at approximately USD 151 million, expands Immedica’s footprint into the U.S. market and enhances our operational capabilities, paving the way for future growth. The transaction, expected to close in Q1 2025, reflects Immedica’s strategic focus on addressing significant unmet medical needs in rare diseases. Information relating to the transaction is available online at https://www.sec.gov   www.immedica.com   #Immedica #ImmedicaPharma #MarinusPharma #RareDiseases “

Novartis Bangladesh's majority shares are to be acquired by Radiant Pharma. Novartis (Bangladesh) Limited and Radiant Pharmaceuticals Limited have signed a Share Purchase Agreement.

CVC Credit is pleased to announce that it has provided debt facilities to support the joint acquisition of Immedica Pharma, a leading Swedish pharmaceutical company, by global investment firm KKR and Nordic healthcare investment firm Impilo. Moris Nachmias, Managing Director at CVC Credit, said: “Immedica has an impressive track record of profitable growth and strong financial performance since its founding in 2018. We look forward to supporting their continued expansion in the years ahead.”   simone zacchi, Partner at CVC Credit, added: “Being part of the CVC Network has meant our team have been able leverage the knowledge of our Private Equity Healthcare team to help deliver this investment opportunity. We are also pleased to be partnering with KKR again, having supported several of their recent acquisitions including APRIL Group.” https://lnkd.in/eQfCyEFw

Important to hear the NHS perspective on the pharmacy of tomorrow in addition to the sector’s